Functional NETs
Showing 1 - 25 of >10,000
Chromogranin A as Blood Marker in Cancer Patients
Completed
- Gastric Neoplasms
- +3 more
- BRAHMS CgA II KRYPTOR
-
Palo Alto, California
- +3 more
Dec 19, 2022
Neuroendocrine Tumors Trial in Worldwide (177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine
Recruiting
- Neuroendocrine Tumors
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
- +4 more
-
Palo Alto, California
- +30 more
Dec 14, 2022
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor Trial in Newport Beach, Denver, Dallas (nab-sirolimus)
Not yet recruiting
- Neuroendocrine Tumors
- +4 more
-
Newport Beach, California
- +2 more
Aug 16, 2023
HRQoL During PRRT in Patients With NETs
Completed
- Neuroendocrine Tumors
- +2 more
- (no location specified)
Jun 16, 2022
Effectiveness and Outcomes Associated With Lutathera Treatment
Active, not recruiting
- Gastroenteropancreatic Neuroendocrine Tumor
-
Alessandria, Italy
- +17 more
May 4, 2022
Cerebral Palsy Trial in Kirsehir (Conventional Exercises, Sensory Integration Therapy)
Completed
- Cerebral Palsy
- Conventional Exercises
- Sensory Integration Therapy
-
Kirsehir, Merkez, TurkeyAtahan TURHAN
Jul 21, 2023
Neutrophils and Eosinophils in Severe Asthma Treated With
Not yet recruiting
- Asthma
-
Paris, FranceHôpital Bichat-Claude Bernard
Jul 25, 2023
Nonfunctioning Small Neuroendocrine Pancreatic Incidentaloma
Active, not recruiting
- Neuroendocrine Tumors
-
Louvain, Belgium
- +21 more
Oct 8, 2021
Preoperative Imaging in Small Bowel Neuroendocrine Tumors
Recruiting
- Neuroendocrine Tumors
- +2 more
- preoperative imaging
-
Nancy, France
- +1 more
Feb 9, 2022
Verification of Neutrophil Extracellular Trap Net Related
Not yet recruiting
- Acute-On-Chronic Liver Failure
- (no location specified)
Jun 11, 2023
Neuroendocrine Tumors - Patient Reported Outcomes
Enrolling by invitation
- Neuroendocrine Tumors
- +3 more
-
Gainesville, Florida
- +13 more
Jul 7, 2022
Collect Somatuline® Injector Device Preferences of Patients
Not yet recruiting
- Neuroendocrine Tumors
- (no location specified)
Jun 19, 2023
Brain Injury Traumatic Severe, Disorder of Consciousness, Brain Injuries Trial (Active Transcranial alternative current
Not yet recruiting
- Brain Injury Traumatic Severe
- +2 more
- Active Transcranial alternative current stimulation
- SHAM Transcranial alternative current stimulation
- (no location specified)
Apr 17, 2023
DOTATOC PET/CT for Imaging NET Patients
Recruiting
- Neuroendocrine Tumors
- +15 more
- 68Ga-DOTATOC PET/CT
- 18F-FDG PET/CT
-
Vancouver, British Columbia, CanadaBC Cancer
Nov 2, 2022
Gastroenteropancreatic Neuroendocrine Tumours
Recruiting
- Gastroenteropancreatic Neuroendocrine Tumor
- 68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included
-
Milano, ItalyIrccs San Raffaele
Nov 24, 2023
Neuroendocrine Tumors, Gastrointestinal Tumors, Carcinoid Tumors Trial in Denver, Kansas City, Nashville (Lanreotide, Y-90
Terminated
- Neuroendocrine Tumors
- +2 more
- Lanreotide
- Y-90 microspheres
-
Denver, Colorado
- +2 more
Jul 5, 2022
NETs Formation vs. Suicidal Mechanism of NETs Formation During
Active, not recruiting
- Pre-Eclampsia
-
Nimes, FranceCHU Nimes
Jul 20, 2022
Neuroendocrine Tumors Trial in Seoul (Lanreotide autogel)
Recruiting
- Neuroendocrine Tumors
- Lanreotide autogel
-
Seoul, Korea, Republic ofChanghoon Yoo
Jul 18, 2022
Gastroenteropancreatic Neuroendocrine Tumor Trial in China (Lanreotide autogel)
Completed
- Gastroenteropancreatic Neuroendocrine Tumor
- Lanreotide autogel
-
Sichuan, Chengdu, China
- +13 more
Jan 16, 2023
Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT) Trial in Ferrara (Lutetium-177 (177Lu)-DOTATOC, Yttrium-90
Recruiting
- Neuroendocrine Tumors
- Peptide Receptor Radionuclide Therapy (PRRT)
- Lutetium-177 (177Lu)-DOTATOC
- +4 more
-
Ferrara, ItalyUniversity Hospital of Ferrara
Mar 5, 2021
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System Trial in Germany (Pasireotide LAR
Completed
- Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
- Pasireotide LAR followed by Pasireotide LAR + Everolimus
- Everolimus followed by Pasireotide LAR + Everolimus
-
Bad Berka, Germany
- +3 more
Dec 17, 2020
Neuroendocrine Tumors Trial in Australia (64Cu-SARTATE)
Recruiting
- Neuroendocrine Tumors
-
Kingswood, New South Wales, Australia
- +3 more
May 17, 2022
Diabetes and Cognitive Impairment Based on Simultaneous EEG-fMRI
Recruiting
- Type 2 Diabetes
- +2 more
- Cognitive assessments
- +3 more
-
Nanjing, Jiangsu, ChinaDepartment of Radiology, the Affiliated Drum Tower Hospital of N
Oct 23, 2022
Neuroendocrine Tumors Trial in Lexington (Telotristat (Low-Dose), Telotristat (High-Dose))
Recruiting
- Neuroendocrine Tumors
- Telotristat (Low-Dose)
- Telotristat (High-Dose)
-
Lexington, KentuckyMarkey Cancer Center
Nov 10, 2022
Stroke Trial in Austria, Germany, Italy (DC-Stimulator to apply tDCS, DC-Stimulator to apply Sham tDCS)
Active, not recruiting
- Stroke
- DC-Stimulator to apply tDCS
- DC-Stimulator to apply Sham tDCS
-
Wien, Austria
- +10 more
May 3, 2021